Newborn blood spot screening for galactosemia, tyrosiemia type I, homocystinuria,sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease and severe combined immunodeficiency

Alberta STE Report written under contract with the Alberta Health Technologies Decision Process (AHTDP).

This STE report examines the safety, screening accuracy, therapeutic efficacy/effectiveness, cost-effectiveness, budget impact, and health system readiness of newborn screening for seven conditions (galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency), contextualized to the Alberta setting.

Section Authors:

• Section One – Background and Context: Arianna Waye
• Section Two – Social and System Demographics: Arianna Waye
• Section Three – Technology Effectiveness and Safety: Mohamed El Shayeb, Bing Guo, Paula Corabian
• Section Four – Economic Analysis: Charles Yan, Arianna Waye, Ilke Akpinar, Anderson Chuck
• Section Five – Conclusion: Anderson Chuck, Arianna Waye
• Information Specialist: Dagmara Chojecki